Press Releases Zealand Pharma A/S

Stocks

ZEAL

DK0060257814

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 04:51:07 2026-06-09 am EDT			5-day change	1st Jan Change
274.70 ^DKK	+8.88%		-10.11%	-41.27%

03:47am	U.S. Futures Rise, European Stocks Mixed	DJ
Jun. 08	Major European indices flat - Zealand Pharma plunges	FW

Press Releases

Jun. 08	Zealand Pharma - Transactions related to share buy-back program (week 23, 2026)	GL
Jun. 08	Zealand Pharma increases its share capital as a result of the exercise of employee warrants	GL
Jun. 07	Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis	GL
Jun. 05	New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity	GL
Jun. 02	Zealand Pharma to participate in the Goldman Sachs Global Healthcare Conference	GL
Jun. 01	Zealand Pharma - Transactions related to share buy-back program (week 22, 2026)	GL
Jun. 01	Transactions in Zealand Pharma shares and or related securities by persons discharging managerial responsibilities and or their closely associated persons	AQ
May. 29	Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons	GL
May. 27	Zealand Pharma to participate in the Jefferies Global Healthcare Conference	GL
May. 27	Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions	GL
May. 26	Zealand Pharma - Transactions related to share buy-back program (week 21, 2026)	GL
May. 26	Resolutions from Zealand Pharma's Extraordinary General Meeting 2026	GL
May. 19	Gubra Appoints Adam Lange as Head of Investor Relations	AQ
May. 14	Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)	GL
May. 08	Zealand Pharma A/S : Q1 Financial Results / Interim Report First Quarter 2026	PU
May. 08	Zealand Pharma A/S : Interim Report for Q1 2026	PU
May. 07	Zealand Pharma - Execution framework for share buy-back program	GL
May. 07	Zealand Pharma Announces Financial Results for the First Three Months of 2026	GL
May. 07	Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program	GL
May. 07	Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program	AQ
May. 01	The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting	GL
May. 01	Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026	GL
Apr. 30	Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results	GL
Apr. 29	Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management	GL
Apr. 28	Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial	GL